SPRB — SPRUCE BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1683553 ·
Last close
$58.65
Market Cap
$168.56M
52W High
$58.92
52W Low
$40.33
ADV30
55,949
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,987,000 | -12,266,000 | 56,166,000 | 54,080,000 | 21,518,000 |
| Dec 2025 | 0 | — | -11,100,000 | -14,646,000 | 53,021,000 | 48,906,000 | 10,505,000 |
| Sep 2025 | 0 | — | -8,229,000 | -8,212,000 | 15,313,000 | 10,669,000 | 9,927,000 |
| Jun 2025 | 0 | — | -2,692,000 | -2,067,000 | 21,820,000 | 16,387,000 | 8,640,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,332,000
Investing CF
$-10,000
Financing CF
$57,808,000
CapEx
$-10,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-50.96
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-301,500,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-36,463,000
Pretax Income TTM
$-37,191,000
Interest Exp TTM
$728,000
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,513,000 | -38,966,000 | 53,021,000 | 10,505,000 | — | -33,327,000 |
| Dec 2024 | 4,911,000 | -56,151,000 | -53,036,000 | 45,209,000 | 16,388,000 | — | -55,964,000 |
| Dec 2023 | 10,089,000 | -51,993,000 | -47,919,000 | 103,946,000 | 27,437,000 | — | -33,275,000 |
| Dec 2022 | 0 | -47,283,000 | -46,180,000 | 85,648,000 | 17,162,000 | — | -41,683,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$8.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | $168.39M | $23.18 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $172.23M | $4.55 | — |
| MENS | Jyong Biotech Ltd. | $164.80M | $2.22 | — |
| DERM | Journey Medical Corp | $175.79M | $7.91 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $177.67M | $1.26 | — |
News headlines (Yahoo Finance, 1h cache)
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
2026-08-24 12:00 · Yahoo
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-12 13:00 · Yahoo
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
2026-07-08 20:01 · Yahoo
Spruce Biosciences Joins the Russell 3000® Index
2026-06-29 12:00 · Yahoo
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
2026-06-15 12:00 · Yahoo
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
2026-06-08 20:05 · Yahoo
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
2026-08-12 12:00 · Yahoo
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
2026-08-03 12:00 · Yahoo
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2026-07-27 12:00 · Yahoo
American Express, Biogen upgraded: Wall Street's top analyst calls
2026-07-13 13:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.